Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q2 2022 · 10-Q
Revenue$123.47M$123.47M+21.4% vs Q2 2021 Net Income$17.35M$17.35M+123.3% vs Q2 2021 EPS Diluted$0.33$0.33+106.3% vs Q2 2021 Gross Profit$63,356,000+33.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$2,815,000−91.2% Free Cash Flowderived-$3,147,000N/M Margins · derivedGross margin51.3%+4.7 pt vs Q2 2021
Operating margin20.1%+9.7 pt vs Q2 2021
Net margin14.0%+6.4 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end